Report Library

All Reports
Datamonitor Healthcare Oncology Disease Analysis: Gastric Cancer

November 16, 2022

HER2, PD-1, and receptor tyrosine kinases (RTKs) are the most common molecular targets for both branded and pipeline drugs. However, the treatment landscape remains dominated by non-targeted chemotherapies, with most targeted agents confined to one or two treatment settings, where they are typically administered alongside chemotherapy. 

Despite a failed expansion to front-line therapy, the VEGFR antagonist Cyramza was the most successful targeted therapy in gastric cancer prior to the launch of immune checkpoint inhibitors, having become the standard of care in second-line disease. 

This Datamonitor Healthcare report contains a Disease Analysis module.

Indications Covered: Gastric Cancer
Back to the top Back to the top